Cabezas Quintario, María AntoniaZenzola, VíctorArguelles, MiguelPérez Fernández, Elia2025-01-282025-01-282018-10-31MA Cabezas-Quintario, V Zenzola, M Arguelles, E Perez-Fernandez. Androgen Receptor as Prognostic Marker in Triple-Negative Breast Cancer Patients. Journal of Medical & Surgical Pathology [Internet]. 2018;03(04). Available from: http://dx.doi.org/10.4172/2472-4971.10001702472-497110.4172/2472-4971.1000170https://hdl.handle.net/20.500.14352/116473Purpose: The purpose of this study was to assess the prognostic impact of androgen receptor (AR) expression in patients with triple-negative breast cancer (TNBC). Methods/patients: 101 patients treated for primary TNBC without distant metastasis from 1999 to 2015 were identified from breast surgery database. Kaplan-Meier and Cox regression models evaluated disease-free survival (DFS) and overall survival (OS). Results: AR expression was positive (IHC>1%) in 40% of patients. OS at 36 and 60 months was 86% and 80% in AR-negative patients, and 100% and 96% in AR-positive patients (log rank test 0.036). DFS at 36 and 60 months was 78% and 68% in AR-negative and 92% and 89% in AR-positive (log rank test 0.075). Conclusions: Patients without AR expression have a significant correlation with poor outcomeengAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/journal articlehttps://doi.org/10.4172/2472-4971.1000170https://www.longdom.org/open-access/androgen-receptor-as-prognostic-marker-in-triplenegative-breast-cancer-patients-2472-4971-1000170.pdfhttps://www.longdom.org/open-access/androgen-receptor-as-prognostic-marker-in-triplenegative-breast-cancer-patients-42947.htmlopen access616.1/.9Androgen receptorTriple-negative breast cancerPrognosisCiencias BiomédicasMedicina32 Ciencias Médicas3207 Patología